Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018

被引：24

作者：

Lombardi, Pasquale ^{[1
]}

Marandino, Laura ^{[1
]}

De Luca, Emmanuele ^{[2
]}

Zichi, Clizia ^{[2
]}

Reale, Maria Lucia ^{[3
]}

Pignataro, Daniele ^{[3
]}

Di Stefano, Rosario F. ^{[3
]}

Ghisoni, Eleonora ^{[1
]}

Mariniello, Annapaola ^{[3
]}

Trevisi, Elena ^{[3
]}

Leone, Gianmarco ^{[3
]}

Muratori, Leonardo ^{[3
]}

La Salvia, Anna ^{[3
,5
]}

Sonetto, Cristina ^{[3
,6
]}

Leone, Francesco ^{[1
,7
]}

Aglietta, Massimo ^{[1
]}

Novello, Silvia ^{[3
]}

Scagliotti, Giorgio, V ^{[3
]}

Perrone, Francesco ^{[4
]}

Di Maio, Massimo ^{[2
]}

机构：

[1] Univ Turin, Candiolo Canc Inst FPO IRCCS, Dept Oncol, Candiolo, TO, Italy

[2] Univ Turin, Ordine Mauriziano Hosp, Dept Oncol, Turin, Italy

[3] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Orbassano, TO, Italy

[4] Ist Nazl Studio & Cura Tumori Fdn Giovanni Pascal, Clin Trials Unit, Naples, Italy

[5] 12 Octubre Univ Hosp, Dept Oncol, Madrid, Spain

[6] IRCCS Natl Canc Inst, Gynecol Oncol, Milan, Italy

[7] Osped Inferm Biella, Dept Oncol, Biella, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 146卷

关键词：

Health-related quality of life; Colorectal cancer; Endpoints; Patient-reported outcomes; Randomized controlled trials; KRAS WILD-TYPE; CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED-CONTROLLED-TRIAL; ADVANCED RECTAL-CANCER; OPEN-LABEL; COLON-CANCER; DOUBLE-BLIND; ADJUVANT CHEMOTHERAPY; 1ST-LINE TREATMENT; NON-INFERIORITY;

D O I：

10.1016/j.critrevonc.2020.102877

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In this study, our aim was to describe quality of life (QoL) prevalence and heterogeneity in QoL reporting in colorectal cancer phase III trials. Methods: We included all phase III trials evaluating anticancer drugs in colorectal cancer patients published between 2012 and 2018 by 11 major journals. Results: Out of the 67 publications identified, in 41 (61.2 %) QoL was not listed among endpoints. Out of 26 primary publications of trials including QoL among endpoints, QoL results were not reported in 10 (38.5 %). Overall, no QoL data were available in 51/67 (76.1 %) primary publications. In particular, in the metastatic setting, QoL data were not available in 12/18 (66.7 %) trials with primary endpoint overall survival, and in 20/29 (69.0 %) trials with other primary endpoints. Conclusions: QoL was absent in a high proportion of recently published phase III trials in colorectal cancer, even in trials of second or further lines, where attention to QoL should be particularly high.

引用

页数：14

共 81 条

[1] Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial [J].

Alberts, Steven R. ;

Sargent, Daniel J. ;

Nair, Suresh ;

Mahoney, Michelle R. ;

Mooney, Margaret ;

Thibodeau, Stephen N. ;

Smyrk, Thomas C. ;

Sinicrope, Frank A. ;

Chan, Emily ;

Gill, Sharlene ;

Kahlenberg, Morton S. ;

Shields, Anthony F. ;

Quesenberry, James T. ;

Webb, Thomas A. ;

Farr, Gist H., Jr. ;

Pockaj, Barbara A. ;

Grothey, Axel ;

Goldberg, Richard M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13) :1383-1393

[2] Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial [J].

Andre, Thierry ;

Vernerey, Dewi ;

Mineur, Laurent ;

Bennouna, Jaafar ;

Desrame, Jerome ;

Faroux, Roger ;

Fratte, Serge ;

de Larauze, Marine Hug ;

Paget-Bailly, Sophie ;

Chibaudel, Benoist ;

Bez, Jeremie ;

Dauba, Jerome ;

Louvet, Christophe ;

Lepere, Celine ;

Dupuis, Olivier ;

Becouarn, Yves ;

Mabro, May ;

Egreteau, Joelle ;

Bouche, Olivier ;

Deplanque, Gael ;

Ychou, Marc ;

Galais, Marie Pierre ;

Ghiringhelli, Francois ;

Dourthe, Louis Marie ;

Bachet, Jean-Baptiste ;

Khalil, Ahmed ;

Bonnetain, Franck ;

de Gramont, Aimery ;

Taieb, Julien .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) :1469-+

[3]

[Anonymous], 2014, Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies

[4]

[Anonymous], 2015, J NATL CANC I

[5] Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02) [J].

Aparicio, T. ;

Lavau-Denes, S. ;

Phelip, J. M. ;

Maillard, E. ;

Jouve, J. L. ;

Gargot, D. ;

Gasmi, M. ;

Locher, C. ;

Adhoute, X. ;

Michel, P. ;

Khemissa, F. ;

Lecomte, T. ;

Provencal, J. ;

Breysacher, G. ;

Legoux, J. L. ;

Lepere, C. ;

Charneau, J. ;

Cretin, J. ;

Chone, L. ;

Azzedine, A. ;

Bouche, O. ;

Sobhani, I. ;

Bedenne, L. ;

Mitry, E. .

ANNALS OF ONCOLOGY, 2016, 27 (01) :121-127

[6] Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) [J].

Aparicio, Thomas ;

Ghiringhelli, Francois ;

Boige, Valerie ;

Le Malicot, Karine ;

Taieb, Julien ;

Bouche, Olivier ;

Phelip, Jean-Marc ;

Francois, Eric ;

Borel, Christian ;

Faroux, Roger ;

Dahan, Laetitia ;

Jacquot, Stephane ;

Genet, Dominique ;

Khemissa, Faiza ;

Suc, Etienne ;

Desseigne, Francoise ;

Texereau, Patrick ;

Lepage, Come ;

Bennouna, Jaafar .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) :674-+

[7] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[8] Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial [J].

Breugom, A. J. ;

van Gijn, W. ;

Muller, E. W. ;

Berglund, A. ;

van den Broek, C. B. M. ;

Fokstuen, T. ;

Gelderblom, H. ;

Kapiteijn, E. ;

Leer, J. W. H. ;

Marijnen, C. A. M. ;

Martijn, H. ;

Kranenbarg, E. Meershoek-Klein ;

Nagtegaal, I. D. ;

Pahlman, L. ;

Punt, C. J. A. ;

Putter, H. ;

Roodvoets, A. G. H. ;

Rutten, H. J. T. ;

Steup, W. H. ;

Glimelius, B. ;

van de Velde, C. J. H. .

ANNALS OF ONCOLOGY, 2015, 26 (04) :696-701

[9] Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study [J].

Bujko, K. ;

Wyrwicz, L. ;

Rutkowski, A. ;

Malinowska, M. ;

Pietrzak, L. ;

Krynski, J. ;

Michalski, W. ;

Oledzki, J. ;

Kusnierz, J. ;

Zajac, L. ;

Bednarczyk, M. ;

Szczepkowski, M. ;

Tarnowski, W. ;

Kosakowska, E. ;

Zwolinski, J. ;

Winiarek, M. ;

Wisniowska, K. ;

Partycki, M. ;

Beczkowska, K. ;

Polkowski, W. ;

Stylinski, R. ;

Wierzbicki, R. ;

Bury, P. ;

Jankiewicz, M. ;

Paprota, K. ;

Lewicka, M. ;

Cisel, B. ;

Skorzewska, M. ;

Mielko, J. ;

Bebenek, M. ;

Maciejczyk, A. ;

Kapturkiewicz, B. ;

Dybko, A. ;

Hajac, L. ;

Wojnar, A. ;

Lesniak, T. ;

Zygulska, J. ;

Jantner, D. ;

Chudyba, E. ;

Zegarski, W. ;

Las-Jankowska, M. ;

Jankowski, M. ;

Kolodziejski, L. ;

Radkowski, A. ;

Zelazowska-Omiotek, U. ;

Czeremszynska, B. ;

Kepka, L. ;

Kolb-Sielecki, J. ;

Toczko, Z. ;

Fedorowicz, Z. .

ANNALS OF ONCOLOGY, 2016, 27 (05) :834-842

[10] Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension [J].

Calvert, Melanie ;

Blazeby, Jane ;

Altman, Douglas G. ;

Revicki, Dennis A. ;

Moher, David ;

Brundage, Michael D. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (08) :814-822

← 1 2 3 4 5 6 7 8 9 →